National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Understanding Cancer Series: Angiogenesis
< Back to Main
In English     En español
    Posted: 01/28/2005    Reviewed: 09/01/2006
Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
The Cancer Genome Atlas Reports Brain Tumors Study

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Slide 24  :  Drugs That Block Extracellular Matrix Breakdown <  >  

A third group of angiogenesis inhibitors are directed against one of the initial products made by growing endothelial cells, namely, the MMPs, enzymes that catalyze the breakdown of the extracellular matrix. Because breakdown of the matrix is required before endothelial cells can migrate into surrounding tissues and proliferate into new blood vessels, drugs that target MMPs also can inhibit angiogenesis.

Several synthetic and naturally occurring molecules that inhibit the activity of MMPs are currently being tested to see if interfering with this stage in the process of angiogenesis will prolong the survival of cancer patients.

Drugs That Block Extracellular Matrix Breakdown

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov